Stockscreener 앱 받기
57.69
0.02%
0.010
시간 외 거래:
57.65
-0.04
-0.07%
전일 마감가:
$57.68
열려 있는:
$57.7
하루 거래량:
3.59M
Relative Volume:
2.35
시가총액:
$1.67B
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-18.91
EPS:
-3.05
순현금흐름:
$-98.17M
1주 성능:
+0.02%
1개월 성능:
+87.12%
6개월 성능:
+477.48%
1년 성능:
+511.12%
1일 변동 폭
$57.64
$57.80
1주일 범위
$57.61
$57.86
52주 변동 폭
$5.6652
$57.86
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
57.69 | 1.67B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Piper Sandler | Overweight |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-26 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-05-22 | 재개 | H.C. Wainwright | Buy |
| 2024-12-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-11-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 개시 | Evercore ISI | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-09-14 | 개시 | Berenberg | Buy |
| 2023-08-09 | 개시 | Stifel | Buy |
| 2023-06-15 | 개시 | Barclays | Overweight |
| 2023-01-04 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | CapitalOne | Overweight |
| 2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 개시 | JP Morgan | Overweight |
| 2021-08-12 | 개시 | SVB Leerink | Outperform |
| 2021-06-21 | 개시 | Piper Sandler | Overweight |
| 2020-06-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 개시 | ROTH Capital | Buy |
| 2019-11-25 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-25 | 개시 | UBS | Buy |
| 2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
Aug Ideas: Is RAPT Therapeutics Inc a speculative investmentMarket Activity Report & Reliable Trade Execution Plans - baoquankhu1.vn
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders - marketscreener.com
RAPT Therapeutics Proposed Sale to GSK Under Investigation - intellectia.ai
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - Business Wire
GSK's Acquisition Highlights Trend Towards Convenience-Focused D - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-JHG, FOLD, RAPT, and EXAS - The Malaysian Reserve
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy - MSN
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
Rapt Therapeutics stock reaches 52-week high at $57.71 By Investing.com - Investing.com Nigeria
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 12-Month HighStill a Buy? - MarketBeat
Rapt Therapeutics stock reaches 52-week high at $57.71 - Investing.com
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Why did RAPT stock surge 63% in pre-market today? - MSN
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal - MSN
GSK acquires RAPT Therapeutics for $2.2bn - MSN
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Biggest stock movers Tuesday: NVDA, RAPT, and more - MSN
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
RAPT Therapeutics (RAPT) Receives Downgrade to Equal-Weight by B - GuruFocus
Barclays Reaffirms Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT) - MarketBeat
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
Rapt Therapeutics stock hits 52-week high at $57.62 - Investing.com
RTW Biotech Opp.GSK to acquire RAPT Therapeutics - Research Tree
Leerink Partners Downgrades RAPT Therapeutics(RAPT.US) to Hold Rating, Cuts Target Price to $58 - 富途牛牛
Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech - Blockonomi
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn - European Pharmaceutical Review
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades - Investing.com Nigeria
GSK to buy Rapt Therapeutics in deal valued at $2.2B - MSN
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades By Investing.com - Investing.com Canada
RTW Biotech welcomes GSK deal to buy RAPT Therapeutics - marketscreener.com
Rapt Therapeutics (NASDAQ:RAPT) Downgraded to "Hold" Rating by Clear Str - MarketBeat
Rapt Therapeutics (RAPT) Stock: GSK Snaps Up Biotech in $2.2 Billion Deal - CoinCentral
GSK enters agreement to acquire RAPT Therapeutics - marketscreener.com
UK: GSK agrees acquisition of RAPT Therapeutics in transaction valued at US$2.2bn - Investors in Healthcare
Aug Rallies: What analysts say about RAPT Therapeutics Inc stockMarket Trend Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Halper Sadeh Investigates Calavo, RAPT, and Confluent Shareholder Rights - Intellectia AI
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
GSK to buy RAPT Therapeutics for $2.2 billion - Classic Rock 103.5 WIMZ
GSK announces $2.2 billion agreement to acquire RAPT Therapeutics By Investing.com - Investing.com Nigeria
Why Rapt Therapeutics Stock Soared Today - The Globe and Mail
GSK to Acquire RAPT Therapeutics for $2.2 Billion, Bolstering Food Allergy Pipeline - NAI500
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.25%
자본화:
|
볼륨(24시간):